Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292

Delayed Quote. Delayed  - 07/22 05:35:29 pm
4612.5 GBp   +1.97%
07/19DJValeant Gets FDA Panel Recommendation for Psoriasis Drug
07/19DJASTRAZENECA : Gets EU Approval for Qtern to Treat Type 2 Diabetes
07/19 ASTRAZENECA : QTERN (saxa/dapa) EU approved for type-2 diabetes
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

AstraZeneca Buys Back 318283 Shares

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/30/2012 | 12:23pm CEST

AstraZeneca PLC (>> AstraZeneca plc) said Monday it has purchased 318,283 ordinary shares on April 27 at a price of 2666 pence per share for cancellation.

-Shares at 1005 GMT up 1%, at 2704 pence, valuing the company at GBP34 billion.

-By Mark Shapland, Dow Jones Newswires; +44 207 8429358; mark.shapland@dowjones.com

Stocks mentioned in the article : AstraZeneca plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA PLC
07/20 ASTRAZENECA : Senators Collins, McCaskill Seek More Information on AstraZeneca's..
07/20 ASTRAZENECA : McCaskill Requests Information from AstraZeneca on Popular Drug Cr..
07/19DJValeant Gets FDA Panel Recommendation for Psoriasis Drug
07/19DJASTRAZENECA : Gets EU Approval for Qtern to Treat Type 2 Diabetes
07/19 ASTRAZENECA : QTERN (saxa/dapa) EU approved for type-2 diabetes
07/19 ASTRAZENECA : Qtern Gets European Approval For Type 2 Diabetes
07/18 ASTRAZENECA : TAGRISSO® (OSIMERTINIB) Met Primary Endpoint in Phase III 2nd-Line..
07/18 LONDON MARKET OPEN : ARM Leads Rising Market But Tour Operators Down
07/18DJASTRAZENECA : Tagrisso Met Primary Endpoint in Lung Cancer Trial
07/18 TOP NEWS : AstraZeneca Gets Strong Results From Tagrisso Trial
More news
Sector news : Pharmaceuticals - NEC
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJBAYER : 2Q 2016 -- Forecast
07/22DJMonsanto Wins EU Nod for New Biotech Soybeans
07/21DJBIOGEN : Announces CEO Search, Lifts Guidance--2nd Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/22 For The Real Relypsa Puzzle Look Beyond The Takeover
07/22 BIOTECH FORUM DAILY DIGEST : Relypsa Gets Bought Out, Biogen's Big Beat, Biotech..
07/21 Big Pharma Dominates Healthcare But Caregivers Are Top Sector Yield Dogs In J..
07/21 FDA Experts Back Brodalumab, With Warnings
07/20 Mylan launches generic version of Crestor in U.S.; shares up 4%
Advertisement
Financials ($)
Sales 2016 23 079 M
EBIT 2016 5 372 M
Net income 2016 2 528 M
Debt 2016 10 708 M
Yield 2016 4,61%
P/E ratio 2016 29,09
P/E ratio 2017 27,55
EV / Sales 2016 3,81x
EV / Sales 2017 3,87x
Capitalization 77 183 M
More Financials
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 68,0 $
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Edward Bradley Senior VP-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC-0.09%77 183
JOHNSON & JOHNSON21.72%343 913
PFIZER INC.13.82%222 823
NOVARTIS AG-5.13%219 526
ROCHE HOLDING LTD.-9.62%218 832
MERCK & CO., INC.11.36%162 815
More Results